spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  gastroenteritis 

 HSMN NewsFeed - 19 Nov 2021
BioMarin Receives FDA Approval for VOXZOGO(TM) (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jan 2020
SutroVax Announces Executive Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Biopharmaceuticals Cardiology Reimbursement
 HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals
 HSMN NewsFeed - 28 May 2019
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
Biopharmaceuticals
 HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 6 Dec 2017
Third Respiratory Assay Now FDA Cleared on Hologic's New Panther Fusion(R) System
Diagnostics FDA Product Launch
 HSMN NewsFeed - 15 Sep 2017
Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 28 Jun 2017
Luminex Corporation Receives CE-IVD Mark for ARIES(R) Norovirus Assay
Diagnostics Regulatory
 HSMN NewsFeed - 5 Jun 2017
BD Receives FDA 510(K) Clearance for Molecular Test for Harmful Intestinal Bacteria Causing Infectious Diarrhea
Diagnostics FDA
 HSMN NewsFeed - 13 Apr 2017
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Jan 2017
Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Feb 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Nov 2015
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 11 Sep 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha(TM) (Evolocumab)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 1 Dec 2014
Cepheid Receives FDA Clearance for Xpert Norovirus, the First On-Demand Molecular Test for Detection of Norovirus
Diagnostics FDA
 HSMN NewsFeed - 7 May 2014
The BD MAX(TM) Enteric Bacterial Panel Receives FDA Clearance to Detect the Most Common Causes of Bacterial Gastroenteritis
Diagnostics FDA
 HSMN NewsFeed - 12 Mar 2014
Pfizer Presents Detailed Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*
Biopharmaceuticals
 HSMN NewsFeed - 3 Mar 2014
U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Drug Delivery Endocrinology FDA
 HSMN NewsFeed - 8 Jan 2014
Ironwood Pharmaceuticals Announces Alignment of Workforce with Priority Growth Platforms
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Oct 2013
Pfizer Receives European Approval For Label Update Regarding The Use Of Prevenar 13 In Certain High-Risk Populations
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 22 May 2012
FDA Approves Levemir(R) for Expanded Use in Children Two to Five Years of Age with Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 16 Dec 2011
Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest Countries
Biopharmaceuticals
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2011
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2010
Prodesse ProAdeno+ Assay Cleared for US Marketing by FDA
Diagnostics FDA
 HSMN NewsFeed - 29 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 May 2010
Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2009
Baxter Announces the Commercial Launch of HYLENEX at ACEP for Use in Pediatric Rehydration
Biopharmaceuticals
 HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals
 HSMN NewsFeed - 3 Apr 2008
FDA Approves Rotarix(R) [Rotavirus Vaccine, Live, Oral], the First Vaccine Licensed to Complete the Rotavirus Immunization Series by Four Months of Age
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2008
LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series 'C' Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Feb 2008
GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Nov 2007
New Data Published in The Lancet Show GSK's ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2007
Merck to Donate Three Million Doses of Gardasil(R), its Cervical Cancer Vaccine, to Support Vaccination Programs in Lowest Income Nations
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2007
Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Sep 2007
New Data Show That GlaxoSmithKline's Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 20 Aug 2007
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Aug 2007
GlaxoSmithKline's Application for Rotarix(R) is Accepted for Review by the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Jul 2007
Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 23 Jul 2007
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Jul 2007
Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 29 May 2007
Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn's Disease
Biopharmacetuicals Gastroenterology FDA
 HSMN NewsFeed - 3 May 2007
Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Feb 2007
FDA Approves First Medication to Treat and Prevent Vomiting in Dogs
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Feb 2007
Merck Updates Prescribing Information for ROTATEQ(R), the Company's Vaccine to Help Prevent Rotavirus Gastroenteritis in Infants and Children
Biopharmaceuticals
 HSMN NewsFeed - 15 Dec 2006
Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 13 Nov 2006
ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2006
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
New Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Data Reinforce Efficacy of TRIZIVIR(R) Alone in Treatment-Naive HIV Patients with Low Viral Load
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Sep 2006
New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Sep 2006
Neose Provides Update on GlycoPEG-GCSF Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2006
Merck and Nicaragua Unveil New Rotavirus Vaccine Demonstration Project at Clinton Global Initiative
Biopharmaceuticals
 HSMN NewsFeed - 28 Aug 2006
Genentech and Biogen Idec Announce Positive Results From a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jul 2006
Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Jun 2006
FDA Approves Merck's GARDASIL(R), the World's First and Only Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2006
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 26 May 2006
Merck to Create New Patient Assistance Program for Vaccines
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2006
Favorable Antiviral Activity and Improved Tolerability Demonstrated by Valopicitabine 200 mg/day in Combination with Pegylated Interferon in an Ongoing Phase IIb Trial in Treatment-Naive Genotype 1 Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Apr 2006
FDA Approves Genzyme's Myozyme(R) for All Patients with Pompe Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Apr 2006
New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Feb 2006
AVANT Announces that the European Regulatory Authorities Have Approved Rotarix(R) Rotavirus Vaccine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Feb 2006
GARDASIL(R), Merck's Investigational Cervical Cancer Vaccine, to Receive Priority Review from the U.S. Food and Drug Administration
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2006
Dr. Moncef Slaoui to Head GlaxoSmithKline Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Feb 2006
FDA Approves Merck's ROTATEQ(R), The Only Vaccine in the U.S. to Prevent Rotavirus Gastroenteritis, a Leading Cause of Severe Infant Diarrhea
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2006
In a New Study Published in New England Journal of Medicine, ROTATEQ(R), Merck's Investigational Rotavirus Vaccine, Prevented 98 Percent of Severe Rotavirus Gastroenteritis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Jan 2006
GlaxoSmithKline's Rotavirus Vaccine Candidate Shown Effective Against Rotavirus Disease
Biopharmaceuticals Gastroenterology
Return to NewsFeed  

 Additional items found! 25

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 25 additional stories matching:
gastroenteritis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.